Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.

Kidney Compass: Sibeprenlimab and the VISIONARY Trial, with Vlado Perkovic, MBBS, PhD, at ERA 2025

Jonathan Barratt, MD, PhD, discusses results from an open-label trial of mezagitamab from ERA 2025. 

Mezagitamab Shows Promise for IgA Nephropathy in Phase 1b Trial, with Jonathan Barratt, MD, PhD

Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.

ERA 2025: Sibeprenlimab Halves Proteinuria in IgAN in Phase 3 VISIONARY Trial

Atacicept May Offer Durable Benefits in IgAN with Ongoing Use, with Jonathan Barratt, MD, PhD

New data from a phase 2 and an OLE trial provide additional insight into the effects of iptacopan in IgA nephropathy. 

ERA 25: Data Underscore Iptacopan’s Effect on Proteinuria and Complement Activation in IgAN

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN. 

Phase 3 ORIGIN Sets Stage for Atacicept in IgA Nephropathy, with Richard Lafayette, MD

Jonathan Barratt, MD, PhD, offers perspective on how the 100-week data from ERA 25 inform the potential of Zikabart.

Understanding Zigakibart's Potential in IgA Nephropathy, with Jonathan Barratt, MD, PhD

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

ERA 2025: Zigakibart Maintains Efficacy Out to 100 Weeks in ADU-CL-19 Trial

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025. 

ERA 2025 Late-Breaking Trials Preview

Vera Therapeutics intends to bring the results before the FDA by the end of 2025; they anticipate an approval and commercial launch in 2026.

Atacicept Achieves Endpoints in Phase 3 ORIGIN Trial for IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.